Recombinant Human C-C Motif Chemokine 27 Protein (CCL27), Active

Name: Recombinant Human C-C Motif Chemokine 27 Protein (CCL27), Active
Brand: Beta LifeScience
SKU: BLC-05501P
Availability: InStock

Collections: All products, Buy cytokines, chemokines, and growth factors for research online, Chemokines and receptors – essential regulators of immune response, High-quality cytokines for advanced research, High-quality recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human C-C Motif Chemokine 27 Protein (CCL27), Active is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 96% as determined by SDS-PAGE and HPLC.
Endotoxin	Less than 1.0 EU/μg as determined by LAL method.
Activity	Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using CCR10 transfected BaF3 cells is in a concentration range of 10-100 ng/ml.
Uniprotkb	Q9Y4X3
Target Symbol	CCL27
Synonyms	ALP; C-C motif chemokine 27; CC chemokine ILC; Ccl27; CCL27_HUMAN; Chemokine (C-C motif) ligand 27; CTACK; CTAK; Cutaneous T cell attracting chemokine; Cutaneous T-cell-attracting chemokine; ESkine; IL 11 R alpha locus chemokine; IL-11 R-alpha-locus chemokine; ILC; PESKY; SCYA27; Skinkine; Small inducible cytokine A27 ; small inducible cytokine subfamily A (Cys-Cys); member 27; Small-inducible cytokine A27
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	Tag-Free
Complete Sequence	FLLPPSTACC TQLYRKPLSD KLLRKVIQVE LQEADGDCHL QAFVLHLAQR SICIHPQNPS LSQWFEHQER KLHGTLPKLN FGMLRKMG
Expression Range	25-112aa
Protein Length	Full Length of Mature Protein
Mol. Weight	10.1 kDa
Research Area	Immunology
Form	Lyophilized powder
Buffer	Lyophilized from a 0.2 µm filtered PBS, pH 7.4
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Chemotactic factor that attracts skin-associated memory T-lymphocytes. May play a role in mediating homing of lymphocytes to cutaneous sites. Binds to CCR10.
Subcellular Location	Secreted.
Protein Families	Intercrine beta (chemokine CC) family
Database References	HGNC: 10626 OMIM: 604833 KEGG: hsa:10850 STRING: 9606.ENSP00000259631 UniGene: PMID: 29295705 CCR10/CCL27 crosstalk mediated drug resistance, contributing to failure of proteasome-inhibitors in multiple myeloma. PMID: 27732933 detected in the nucleus in eczema, cytoplasm in psoriasis PMID: 27193975 CCL27 drives baseline recruitment of Herpes simplex virus-specific CD8 T cells expressing CCR10, while interferon-responsive CXCR3 ligands recruit additional cells in response to virus-driven inflammation. PMID: 28701399 We therefore concluded that the cross talk between TNFa and ROS after keratinocytes was exposed to radiation, triggered CCL27 secretion for subsequent inflammation response. PMID: 27879026 Our study showed that a higher immunostaining of CCL27 in supratumoral epidermis is associated with longer progression-free interval and melanoma-specific survival. PMID: 27325798 Our data supports previous reports showing IL-17 and -23 upregulation in association with Multiple sclerosis and potentially identify a previously unknown involvement for CCL27. PMID: 26295034 NOS2 and CCL27: clinical implications for psoriasis and eczema diagnosis and management. PMID: 25539641 Findings support the notion that CCR10 and its ligand CCL27 may contribute to the skin infiltration of malignant T-cells in mycosis fungoides and adult T-cell leukemia/lymphoma. PMID: 24970722 Our study suggests that CTACK/CCL27 may have a pivotal role in the early stage of psoriasis plaque formation, but should be downregulated in the later stage to induce inflammation characteristic for chronic psoriasis plaques PMID: 24710735 Seventeen mediators were identified in burn wound exudates (concentration range 0.0006-9 ng/mg total protein), including the skin-specific chemokine CCL27. PMID: 23980822 We show that the adult but not prenatal human keratinocytes produce and release large amounts of CCL27. PMID: 24037339 CCL27 chemokine implicates cholesteatoma keratinocytes as contributors in cholesteatoma progression. PMID: 23670528 low CCL27/CCR10 and CXCL12/CXCR4 intratumoral mRNA ratios are associated with melanoma progression PMID: 22526457 Serum concentrations of TARC and CTACK were significantly higher in AD (atopic dermatitis) children than in healthy controls, and correlated with severity of symptoms. PMID: 22017510 IL-1beta-induced CCL27 gene expression in normal human keratinocytes is regulated through the p38 MAPK/MSK1/Mnk1+2 as well as the IKKbeta/NF-kappaB signalling pathways. PMID: 21993219 expression of CCL27 and CCL17 in the inflammatory skin diseases: psoriasis, atopic dermatitis and acute allergic contact dermatitis induced in nickel-sensitive individuals PMID: 21707761 member of cytokine family; a chemokine PMID: 11821893 membrane of cytokine family PMID: 11821900 Serum CTACK levels in patients with atopic dermatitis(AD) and psoriasis vulgaris(pSv) were significantly higher. CTACK was strongly expressed in lesional ke-ratinocytes of patients with AD and PsV. PMID: 12642842 serum levels significantly correlated with disease activity in patients with atopic dermatitis PMID: 14767451 primary Th2-dominated inflammatory reaction in atopic dermatitis induced by TARC leads to an augmented skin-specific inflammatory reaction through CTACK. PMID: 15335355 PSGL-1 interacts with CCL27 (CTACK/ILC/ESkine), a skin-associated chemokine that attracts skin-homing T lymphocytes PMID: 15466853 CCL27 expression is under the control of NF-kappaB, and that NF-kappaB, as indicated by others, may be an attractive target for therapy in inflammatory skin diseases PMID: 15598438 IL-1alpha, TNF-alpha, CCL20, CCL27, and CXCL8 alarm signals are induced in human cells after allergen and irritant exposure PMID: 15679580 CCL28 produced by keratinocytes is mediated by different signal pathways from CCL27, and both CCL27 and CCL28 are involved in the pathogenesis of inflammatory skin diseases. PMID: 16433680 CCR10-CTACK/CCL27 interactions between circulating T cells and keratinocytes would seem to play an important role in the pathophysiology of mycosis fungoides. PMID: 16675558 LTB(4) may enhance TNF-alpha-induced CCL27 production by activating NF-kappaB via the BLT1/G(i/o)/PI3K/ERK pathway in human keratinocytes. PMID: 17581202 Human keratinocyte-derived skin tumors may evade T cell-mediated antitumor immune responses by down-regulating the expression of CCL27 through the activation of epidermal growth factor receptor (EGFR)-Ras-MAPK-signaling pathways. PMID: 18025475 Serum concentrations of CCL17, CCL22, and CCL27 correlate well with the extent and intensity of Atopic dermatitis (AD) in infants. Of the three Th2 chemokines examined, serum CCL27 correlated most significantly with the severity of AD PMID: 18266834 a novel mechanism for the recruitment of CCR10-positive T cells to skin-draining LN following the rapid release of preformed CCL27 from the epidermis PMID: 18453562 Significantly lower serum concentration of CXCL-9, CXCL-10, CCL-17, and IL-18 and higher concentration of CXCL-12 and CCL-27 were found in atopic dermatitis patients under 10 years old when compared to Control. PMID: 19639049

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.